RxDoctor Payments Data

Kristen Ingram, MD

Family Medicine · Salem, INNPI 1689626038

Payments from drug & device makers

$380in general payments, 2019–2025

Across 24 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$81
  • GSK$68
  • E.r. Squibb & Sons, L.L.C.$45
  • Lilly USA, LLC$37
  • Merck$33
  • Sanofi-aventis U.S. LLC$31
  • plus $85 from 6 others

What the payments were for

  • Food & beverage$33588%
  • Education$4512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$380 in reported general payments places this provider in the 40th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$109,060
Medicare patients
180
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide170$205,523
OzempicSemaglutide101$107,170
JardianceEmpagliflozin103$92,432
EliquisApixaban57$55,286
TrulicityDulaglutide46$55,121
JanuviaSitagliptin Phosphate35$27,968
XareltoRivaroxaban21$23,691
Breo ElliptaFluticasone/Vilanterol46$22,252
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$22,191
FarxigaDapagliflozin Propanediol26$20,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,871
MyrbetriqMirabegron17$14,748
Spiriva RespimatTiotropium Bromide28$14,665
SymbicortBudesonide/Formoterol Fumarate45$14,366
Combivent RespimatIpratropium/Albuterol Sulfate28$13,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$37$260,643216 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$18$129,730171 claims
Novo NordiskOzempic$13$107,170101 claims
PfizerEliquis, Prempro$14$58,56270 claims
GSKBreo Ellipta, Trelegy Ellipta$68$38,12362 claims
AstraZenecaFarxiga, Symbicort$81$34,75971 claims
MerckJanuvia$33$27,96835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Salem

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →